MTOR and meningioma: Furthermore, a Phase II clinical trial (NCT03071874) has shown that Vistusertib (AZD2014), a dual mTOR inhibitor, can slow the growth rate of meningiomas in patients with recurrent WHO grade 2 and 3 meningiomas.